contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-promisingly-started-growth-journey-just-beginning

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.

Här är en video där Aiforias verkställande direktör berättar om företaget som en investeringsmöjlighet.                   Inderes              Aiforia as an Investment | Life Science Night Dec. 2, 2024 - Inderes    Time: 2024-12-04 09:00 Jukka Tapaninen, CEO, talks about medical software company Aiforia as an investment.

I Finland finns det en liten Aiforia-hype, och den här nyheten minskar knappast på den.                    Inderes              Aiforia wins new clinical segment client in Turkey - Inderes    Memorial Hospitals Group in Turkey has selected Aiforia as its partner for AI-assisted clinical diagnostics in pathology. Memorial Hospitals Group is the largest private hospital group in Turkey, serving 75,000 patients annually in 11 hospitals.

Analytiker @Antti_Luiro ja @Frans-Mikael_Rostedt & En ny analys av det mycket intressanta företaget Aiforia We reiterate our EUR 4.6 target price and raise our recommendation to Accumulate (was  Reduce). Building of Aiforia’s growth continues and a positive news flow is expected from the company, especially on the sales front, but also on regulatory approvals progressing in Europe. The company’s customer gains have brought predictability to growth, although forecasting risks, especially in terms of growth timing and in the long term also concerning the revenue level, remain high. We believe Aiforia has clear preconditions to grow into one of the long-term winners in its market and after the share price drop (-12%), we find the risk/reward ratio attractive even within a year.                   Inderes              Aiforia: We expect the positive news flow to continue - Inderes    Aiforia’s growth continues and a positive news flow is expected from the company, especially on the sales front, but also on regulatory approvals progressing in Europe.

Aiforias samarbete med Paris sjukhusdistrikt går framåt                    Inderes              Aiforia's collaboration with Paris Hospital District moves forward - Inderes    he start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release,...

This is an exciting company; many see a lot of upside potential… but there are risks as well.  Aiforia’s revenue growth stalled in the first half of the year, particularly in the US, although recent months’ customer wins  suggest that the company is continuing to capture the market. Our near-term forecasts have been reduced significantly and we now see a more likely need for additional capital, but customer wins and good sales prospects have improved visibility on revenue growth. After the share price increase (+17%), we think the stock looks quite correctly priced. We reiterate our EUR 4.6 target price and switch our recommendation to Reduce (previous Accumulate).                   Inderes              Aiforia H1'24: Growth is still gathering momentum - Inderes    Aiforia's revenue growth stalled in the first half of the year, particularly in the US, although recent months’ customer wins  suggest that the company is continuing to capture the market.

Here is some recent news about Aiforia.  Fimlab Laboratories Ltd, Finland’s largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.  The value of the first order is approximately EUR 300,000 for the first year, which is some 7% of our 2024 revenue forecast. The order and the concrete launch of the collaboration again support Aiforia’s strong growth prospects.                   Inderes              Aiforia will provide AI solutions for breast and prostate cancer diagnostics...    Fimlab Laboratories Ltd, Finland's largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.

Här är analytikerns färska kommentarer om företagets nya samarbetsarrangemang.  The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast, prostate, and lung cancer patients. The total value of the contract for Aiforia is around 500 TEUR over three years, which means an annual billing of around 167 TEUR. This makes the contract quite significant for the company, but achieving the growth forecasts for the coming years will obviously require similar successes.                   Inderes              Aiforia selected to provide AI-assisted diagnostics solutions in Castilla y...    The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast,...

Aiforia Technologies

Aiforia has gained a promising first foothold in the clinical segment of digital pathology. We continue to see the company in a good competitive position and on a clear trajectory to grow into one of the long-term winners in its market. On the other hand, poor growth predictability and elevated financing risks argue for some caution in pricing the company's potential.

<p>Aiforia has gained a promising first foothold in the clinical segment of digital pathology. We continue to see the company in a good competitive position and on a clear trajectory to grow into one of the long-term winners in its market. On the other hand, poor growth predictability and elevated financing risks argue for some caution in pricing the company's potential. However, at the current share price, we believe that the company's value creation potential outweighs the risks. </p> 

	2022	23e	24e
Revenue	1.6	2.5	4.5
growth-%	64.89 %	56.23 %	79.15 %
EBIT (adj.)	-11.8	-12.6	-11.2
EBIT-% (adj.)	-731.88 %	-502.95 %	-248.72 %
EPS (adj.)	-0.47	-0.50	-0.43
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	-	-	-
EV/EBITDA	-	-	-

Aiforia: Promisingly started growth journey is just beginning

Aiforia Technologies

Key Estimate Figures28/02

Aiforia Technologies

Key Estimate Figures28/02

Stay up to date with our newsletter